Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Axitinib (off Label)

Axitinib + avelumab Phase 2 (MD Anderson)

Pfizer · Phase 2 · Completed · Enrollment 40

Registry id n/r

ArmPopulationDoseEstimandComparatorEfficacy
Axitinib + avelumabR/M ACC (n = 28 evaluable)axitinib 5 mg twice daily + avelumabSingle armn/rconfirmed objective response rate: 18%, primary analysismedian progression-free survival: 7.3 months, primary analysismedian overall survival: 16.6 months, primary analysis
Axitinib + avelumab, ACC-I subtypeACC-I (exploratory biomarker analysis of 28 patients)as aboveSingle armn/rmedian progression-free survival: 1.8 months, updated analysis; exploratory
Axitinib + avelumab, ACC-II subtypeACC-II (exploratory)as aboveSingle armn/rmedian progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I